BIO
Income statement / Annual
Last year (2023), Bio-Rad Laboratories, Inc.'s total revenue was $2.67 B,
a decrease of 4.67% from the previous year.
In 2023, Bio-Rad Laboratories, Inc.'s net income was -$637.32 M.
See Bio-Rad Laboratories, Inc.’s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
| Period Ended |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
12/31/2014 |
| Operating Revenue |
$2.67 B
|
$2.80 B
|
$2.92 B
|
$2.55 B
|
$2.31 B
|
$2.29 B
|
$2.16 B
|
$2.07 B
|
$2.02 B
|
$2.18 B
|
| Cost of Revenue |
$1.24 B |
$1.23 B |
$1.28 B |
$1.11 B |
$1.05 B |
$1.07 B |
$972.75 M |
$930.09 M |
$897.77 M |
$996.53 M |
| Gross Profit |
$1.43 B |
$1.57 B |
$1.64 B |
$1.44 B |
$1.26 B |
$1.22 B |
$1.19 B |
$1.14 B |
$1.12 B |
$1.18 B |
| Gross Profit Ratio |
0.54 |
0.56 |
0.56 |
0.56 |
0.54 |
0.53 |
0.55 |
0.55 |
0.56 |
0.54 |
| Research and Development
Expenses |
$226.93 M
|
$256.89 M
|
$271.66 M
|
$226.60 M
|
$202.71 M
|
$199.20 M
|
$250.30 M
|
$205.86 M
|
$192.97 M
|
$220.33 M
|
| General & Administrative
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$834.78 M
|
$808.94 M
|
$816.72 M
|
$761.99 M
|
$808.20 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$1.49 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$820.62 M
|
$827.83 M
|
$879.57 M
|
$800.27 M
|
$824.63 M
|
$833.29 M
|
$808.94 M
|
$816.72 M
|
$761.99 M
|
$808.20 M
|
| Other Expenses |
$0.00 |
$44.57 M |
$26.78 M |
$24.49 M |
$26.09 M |
$36.59 M |
$12.20 M |
$14.85 M |
$11.08 M |
$13.01 M |
| Operating Expenses |
$1.05 B |
$1.08 B |
$1.15 B |
$1.03 B |
$1.03 B |
$1.03 B |
$1.06 B |
$1.02 B |
$954.96 M |
$1.03 B |
| Cost And Expenses |
$2.29 B |
$2.32 B |
$2.43 B |
$2.13 B |
$2.08 B |
$2.10 B |
$2.03 B |
$1.95 B |
$1.85 B |
$2.03 B |
| Interest Income |
$100.90 M |
$58.00 M |
$18.90 M |
$18.20 M |
$30.50 M |
$26.60 M |
$19.10 M |
$14.70 M |
$10.10 M |
$13.50 M |
| Interest Expense |
$49.44 M |
$38.11 M |
$1.55 M |
$21.86 M |
$23.42 M |
$23.96 M |
$21.91 M |
$21.94 M |
$21.69 M |
$22.13 M |
| Depreciation &
Amortization |
$192.40 M
|
$177.20 M
|
$176.90 M
|
$175.20 M
|
$174.50 M
|
$138.10 M
|
$148.70 M
|
$142.90 M
|
$131.85 M
|
$149.89 M
|
| EBITDA |
-$608.26 M
|
-$4.49 B
|
$5.63 B
|
$5.10 B
|
$2.46 B
|
$674.72 M
|
$269.52 M
|
$206.40 M
|
$299.34 M
|
$303.59 M
|
| EBITDA Ratio |
-0.23 |
0.24 |
0.22 |
0.23 |
0.17 |
0.16 |
0.13 |
0.13 |
0.15 |
0.14 |
| Operating Income Ratio
|
0.14
|
0.17
|
0.17
|
0.16
|
0.1
|
-0.05
|
0.05
|
0.03
|
0.08
|
0.07
|
| Total Other
Income/Expenses Net |
-$1.23 B
|
-$5.19 B
|
$4.95 B
|
$4.49 B
|
$2.03 B
|
$319.39 M
|
-$15.35 M
|
-$73.94 M
|
-$20.86 M
|
-$18.43 M
|
| Income Before Tax |
-$850.10 M |
-$4.70 B |
$5.44 B |
$4.91 B |
$2.26 B |
$507.36 M |
$97.81 M |
$41.56 M |
$145.85 M |
$131.56 M |
| Income Before Tax Ratio
|
-0.32
|
-1.68
|
1.86
|
1.93
|
0.98
|
0.22
|
0.05
|
0.02
|
0.07
|
0.06
|
| Income Tax Expense |
-$212.78 M |
-$1.08 B |
$1.19 B |
$1.10 B |
$502.41 M |
$146.36 M |
-$16.94 M |
$13.44 M |
$32.75 M |
$42.71 M |
| Net Income |
-$637.32 M |
-$3.63 B |
$4.25 B |
$3.81 B |
$1.76 B |
$361.00 M |
$114.74 M |
$28.13 M |
$113.09 M |
$88.85 M |
| Net Income Ratio |
-0.24 |
-1.29 |
1.46 |
1.5 |
0.76 |
0.16 |
0.05 |
0.01 |
0.06 |
0.04 |
| EPS |
-21.82 |
-121.79 |
142.61 |
127.86 |
58.93 |
12.1 |
4.12 |
0.88 |
3.74 |
3.08 |
| EPS Diluted |
-21.82 |
-121.79 |
140.83 |
126.2 |
58.27 |
11.94 |
4.07 |
0.88 |
3.71 |
3.05 |
| Weighted Average Shares
Out |
$29.21 M
|
$29.79 M
|
$29.83 M
|
$29.77 M
|
$29.84 M
|
$29.84 M
|
$29.66 M
|
$29.44 M
|
$29.19 M
|
$28.88 M
|
| Weighted Average Shares
Out Diluted |
$29.21 M
|
$29.79 M
|
$30.21 M
|
$30.16 M
|
$30.18 M
|
$30.23 M
|
$30.03 M
|
$29.65 M
|
$29.41 M
|
$29.13 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
